Unnatural amino acids in novel antibody conjugates

Future Medicinal Chemistry

Volumn 6, Issue 11, 2014, Pages 1309-1324

  Hallam, Trevor J ^a   Smider, Vaughn V ^b  

^a Sutro Biopharma   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIBODY; ANTIBODY CONJUGATE;

ANIMAL; CHEMISTRY; HUMAN;

AMINO ACIDS; ANIMALS; ANTIBODIES; HUMANS; IMMUNOCONJUGATES;

EID: 84906724230     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.79     Document Type: Review

References (87)

1. Kaufman L, Kaplan W. Preparation of a fluorescent antibody specific for the yeast phase of Histoplasma capsulatum. J. Bacteriol. 82, 729-735 (1961).
2. Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br. J. Clin. Pharmacol. 76(2), 248-262 (2013).
3. Junutula JR, Raab H, Clark S et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26(8), 925-932 (2008).
4. Axup JY, Bajjuri KM, Ritland M et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc. Natl Acad. Sci. USA 109(40), 16101-16106 (2012).
5. Tian F, Lu Y, Manibusan A et al. A general approach to site-specific antibody drug conjugates. Proc. Natl Acad. Sci. USA 111(5), 1766-1771 (2014).
6. Behrens CR, Liu B. Methods for site-specific drug conjugation to antibodies. MAbs 6(1), 46-53 (2013).
7. Shen BQ, Xu K, Liu L et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol. 30(2), 184-189 (2012).
8. Agarwal P, van der Weijden J, Sletten EM, Rabuka D, Bertozzi CR. A Pictet-Spengler ligation for protein chemical modification. Proc. Natl Acad. Sci. USA 110(1), 46-51 (2013).
9. Wu P, Shui W, Carlson BL et al. Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag. Proc. Natl Acad. Sci. USA 106(9), 3000-3005 (2009).
10. Strop P, Liu S-H, Dorywalska M et al. Location matters: Site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem. Biol. 20(2), 161-167 (2013).
11. Jeger S, Zimmermann K, Blanc A et al. Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew. Chem. Int. Ed. 49(51), 9995-9997 (2010).
12. Ambrogelly A, Palioura S, Soll D. Natural expansion of the genetic code. Nat. Chem. Biol. 3(1), 29-35 (2007).
13. Hofer T, Skeffington LR, Chapman CM, Rader C. Molecularly defined antibody conjugation through a selenocysteine interface. Biochemistry 48(50), 12047-12057 (2009).
14. Hofer T, Thomas JD, Burke TR Jr, Rader C. An engineered selenocysteine defines a unique class of antibody derivatives. Proc. Natl Acad. Sci. USA 105(34), 12451-12456 (2008).
15. Fekner T, Chan MK. The pyrrolysine translational machinery as a genetic-code expansion tool. Curr. Opin. Chem. Biol. 15(3), 387-391 (2011).
16. Liu CC, Schultz PG. Adding new chemistries to the genetic code. Annu. Rev. Biochem. 79, 413-444 (2010).
17. Anderson JC, Wu N, Santoro SW, Lakshman V, King DS, Schultz PG. An expanded genetic code with a functional quadruplet codon. Proc. Natl Acad. Sci. USA 101(20), 7566-7571 (2004).
18. Niu W, Schultz PG, Guo J. An expanded genetic code in mammalian cells with a functional quadruplet codon. ACS Chem. Biol. 8(7), 1640-1645 (2013).
19. Hutchins BM, Kazane SA, Staflin K et al. Site-specific coupling and sterically controlled formation of multimeric antibody fab fragments with unnatural amino acids. J. Mol. Biol. 406(4), 595-603 (2011).
20. Jewett JC, Bertozzi CR. Cu-free click cycloaddition reactions in chemical biology. Chem. Soc. Rev. 39(4), 1272-1279 (2010).
21. Liu CC, Mack AV, Tsao ML et al. Protein evolution with an expanded genetic code. Proc. Natl Acad. Sci. USA 105(46), 17688-17693 (2008).
22. Kim CH, Axup JY, Dubrovska A et al. Synthesis of bispecific antibodies using genetically encoded unnatural amino acids. J. Am. Chem. Soc. 134(24), 9918-9921 (2012).
23. Hutchins BM, Kazane SA, Staflin K et al. Selective formation of covalent protein heterodimers with an unnatural amino acid. Chem. Biol. 18(3), 299-303 (2011).
24. Kim CH, Axup JY, Lawson BR et al. Bispecific small molecule-Antibody conjugate targeting prostate cancer. Proc. Natl Acad. Sci. USA 110(44), 17796-17801 (2013).
25. Lu H, Wang D, Kazane S et al. Site-specific antibody-polymer conjugates for siRNA delivery. J. Am. Chem. Soc. 135(37), 13885-13891 (2013).
26. Kazane SA, Sok D, Cho EH et al. Site-specific DNA-Antibody conjugates for specific and sensitive immuno-PCR. Proc. Natl Acad. Sci. USA 109(10), 3731-3736 (2012).
27. Kazane SA, Axup JY, Kim CH et al. Self-Assembled antibody multimers through peptide nucleic acid conjugation. J. Am. Chem. Soc. 135(1), 340-346 (2013).
28. Young TS, Ahmad I, Brock A, Schultz PG. Expanding the genetic repertoire of the methylotrophic yeast Pichia pastoris. Biochemistry 48(12), 2643-2653 (2009).
29. Li H, Sethuraman N, Stadheim TA et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat. Biotechnol. 24(2), 210-215 (2006).
30. Liu W, Brock A, Chen S, Schultz PG. Genetic incorporation of unnatural amino acids into proteins in mammalian cells. Nat. Methods 4(3), 239-244 (2007).
31. Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 22(11), 1393-1398 (2004).
32. Nirenberg MW, Matthaei JH. The dependence of cell-free protein synthesis in E. coli upon naturally occurring or synthetic polyribonucleotides. Proc. Natl Acad. Sci. USA 47, 1588-1602 (1961).
33. Brodel AK, Sonnabend A, Kubick S. Cell-free protein expression based on extracts from CHO cells. Biotechnol. Bioeng. 111(1), 25-36 (2014).
34. Hodgman CE, Jewett MC. Optimized extract preparation methods and reaction conditions for improved yeast cell-free protein synthesis. Biotechnol. Bioeng. 110(10), 2643-2654 (2013).
35. Underwood KA, Swartz JR, Puglisi JD. Quantitative polysome ana-lysis identifies limitations in bacterial cell-free protein synthesis. Biotechnol. Bioeng. 91(4), 425-435 (2005).
36. Zawada JF, Yin G, Steiner AR et al. Microscale to manufacturing scale-up of cell-free cytokine production-A new approach for shortening protein production development timelines. Biotechnol. Bioeng. 108(7), 1570-1578 (2011).
37. Munro S, Pelham HRB. An hsp70-like protein in the ER: Identity with the 78 kd glucose-regulated protein and immunoglobulin heavy chain binding protein. Cell 46(2), 291-300).
38. Yin G, Garces ED, Yang J et al. Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-Translation system. MAbs 4(2), 217-225 (2012).
39. Groff D, Armstrong S, Rivers PJ et al. Engineering toward a bacterial 'endoplasmic reticulum' for the rapid expression of immunoglobulin proteins. MAbs 6(3), 671-678 (2014).
40. Noren CJ, Anthony-Cahill SJ, Griffith MC, Schultz PG. A general method for site-specific incorporation of unnatural amino acids into proteins. Science 244(4901), 182-188 (1989).
41. Hohsaka T, Ashizuka Y, Taira H, Murakami H, Sisido M. Incorporation of nonnatural amino acids into proteins by using various four-base codons in an Escherichia coli in vitro translation system. Biochemistry 40(37), 11060-11064 (2001).
42. Heckler TG, Chang LH, Zama Y, Naka T, Chorghade MS, Hecht SM. T4 RNA ligase mediated preparation of novel 'chemically misacylated' tRNAPheS. Biochemistry 23(7), 1468-1473 (1984).
43. Duffy NH, Dougherty DA. Preparation of translationally competent tRNA by direct chemical acylation. Org. Lett. 12(17), 3776-3779 (2010).
44. Goerke AR, Swartz JR. High-level cell-free synthesis yields of proteins containing site-specific non-natural amino acids. Biotechnol. Bioeng. 102(2), 400-416 (2009).
45. Bundy BC, Swartz JR. Site-specific incorporation of p- propargyloxyphenylalanine in a cell-free environment for direct protein-protein click conjugation. Bioconjug. Chem. 21(2), 255-263 (2010).
46. Albayrak C, Swartz JR. Using E. coli-based cell-free protein synthesis to evaluate the kinetic performance of an orthogonal tRNA and aminoacyl-TRNA synthetase pair. Biochem. Biophys. Res. Commun. 431(2), 291-295 (2013).
47. Young TS, Ahmad I, Yin JA, Schultz PG. An enhanced system for unnatural amino acid mutagenesis in E. coli. J. Mol. Biol. 395(2), 361-374 (2010).
48. Johnson DB, Xu J, Shen Z et al. RF1 knockout allows ribosomal incorporation of unnatural amino acids at multiple sites. Nat. Chem. Biol. 7(11), 779-786 (2011).
49. Loscha KV, Herlt AJ, Qi R, Huber T, Ozawa K, Otting G. Multiple-site labeling of proteins with unnatural amino acids. Angew. Chem. Int. Ed. 51(9), 2243-2246 (2012).
50. Agafonov DE, Huang Y, Grote M, Sprinzl M. Efficient suppression of the amber codon in E. coli in vitro translation system. FEBS Lett. 579(10), 2156-2160 (2005).
51. Lee KB, Kim HC, Kim DM, Kang TJ, Suga H. Comparative evaluation of two cell-free protein synthesis systems derived from Escherichia coli for genetic code reprogramming. J. Biotechnol. 164(2), 330-335 (2012).
52. Hong SH, Ntai I, Haimovich AD, Kelleher NL, Isaacs FJ, Jewett MC. Cell-free protein synthesis from a release factor 1 deficient Escherichia coli activates efficient and multiple site-specific nonstandard amino acid incorporation. ACS Synth. Biol. 3(6), 398-409 (2014).
53. Wang L, Amphlett G, Blattler WA, Lambert JM, Zhang W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci. 14(9), 2436-2446 (2005).
54. Junutula JR, Flagella KM, Graham RA et al. Engineered thio-Trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin. Cancer Res. 16(19), 4769-4778 (2010).
55. Bartelds GM, Krieckaert CL, Nurmohamed MT et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-Term follow-up. JAMA 305(14), 1460-1468 (2011).
56. Zimmerman ES, Heibeck TH, Gill A et al. Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjug. Chem. 25(2), 351-361 (2014).
57. Guarino C, DeLisa MP. A prokaryote-based cell-free translation system that efficiently synthesizes glycoproteins. Glycobiology 22(5), 596-601 (2012).
58. Sazinsky SL, Ott RG, Silver NW, Tidor B, Ravetch JV, Wittrup KD. Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc. Natl Acad. Sci. USA 105(51), 20167-20172 (2008).
59. Jung ST, Reddy ST, Kang TH et al. Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc. Natl Acad. Sci. USA 107(2), 604-609 (2010).
60. Ozawa K, Loscha KV, Kuppan KV, Loh CT, Dixon NE, Otting G. High-yield cell-free protein synthesis for site-specific incorporation of unnatural amino acids at two sites. Biochem. Biophys. Res. Commun. 418(4), 652-656 (2012).
61. Young DD, Young TS, Jahnz M, Ahmad I, Spraggon G, Schultz PG. An evolved aminoacyl-TRNA synthetase with atypical polysubstrate specificity. Biochemistry 50(11), 1894-1900 (2011).
62. Kneepkens EL, Wei JC, Nurmohamed MT et al. Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2013-204185 (2013) (Epub ahead of print).
63. Gauba V, Grunewald J, Gorney V et al. Loss of CD4 T-cell-dependent tolerance to proteins with modified amino acids. Proc. Natl Acad. Sci. USA 108(31), 12821-12826 (2011).
64. Cho H, Daniel T, Buechler YJ et al. Optimized clinical performance of growth hormone with an expanded genetic code. Proc. Natl Acad. Sci. USA 108(22), 9060-9065 (2011).
65. Xiao H, Chatterjee A, Choi SH, Bajjuri KM, Sinha SC, Schultz PG. Genetic incorporation of multiple unnatural amino acids into proteins in mammalian cells. Angew. Chem. Int. Ed. 52(52), 14080-14083 (2013).
66. Plass T, Milles S, Koehler C, Schultz C, Lemke EA. Genetically encoded copper-free click chemistry. Angew. Chem. Int. Ed. 50(17), 3878-3881 (2011).
67. Bargou R, Leo E, Zugmaier G et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321(5891), 974-977 (2008).
68. Cui H, Thomas JD, Burke TR, Jr, Rader C. Chemically programmed bispecific antibodies that recruit and activate T cells. J. Biol. Chem. 287(34), 28206-28214 (2012).
69. Robert Lutz. Antibody-drug conjugates: From bench to bedside and back. Presented at: Plenary Session at the 5th Annual Protein & Antibody Engineering Summit (PEGS). Lisbon, Portugal, 4-8 November 2013.
70. Krop IE, Beeram M, Modi S et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 28(16), 2698-2704 (2010).
71. Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. MAbs 6(1), 34-45 (2014).
72. Wan W, Huang Y, Wang Z et al. A facile system for genetic incorporation of two different noncanonical amino acids into one protein in Escherichia coli. Angew. Chem. Int. Ed. 49(18), 3211-3214 (2010).
73. Shimizu Y, Inoue A, Tomari Y et al. Cell-free translation reconstituted with purified components. Nat. Biotechnol. 19(8), 751-755 (2001).
74. Wang Y, Xu W, Kou X et al. Establishment and optimization of a wheat germ cell-free protein synthesis system and its application in venom kallikrein. Prot. Expr. Purif. 84(2), 173-180 (2012).
75. Nakane PK, Pierce GB Jr. Enzyme-labeled antibodies: Preparation and application for the localization of antigens. J. Histochem. Cytochem. 14(12), 929-931 (1966).
76. Oi VT, Glazer AN, Stryer L. Fluorescent phycobiliprotein conjugates for analyses of cells and molecules. J. Cell Biol. 93(3), 981-986 (1982).
77. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu. Rev. Med. 64, 15-29 (2013).
78. Kim CH, Axup JY, Schultz PG. Protein conjugation with genetically encoded unnatural amino acids. Curr. Opin. Chem. Biol. 17(3), 412-419 (2013).
79. Longstaff DG, Larue RC, Faust JE et al. A natural genetic code expansion cassette enables transmissible biosynthesis and genetic encoding of pyrrolysine. Proc. Natl Acad. Sci. USA 104(3), 1021-1026 (2007).
80. Ou W, Uno T, Chiu HP et al. Site-specific protein modifications through pyrroline-carboxy-lysine residues. Proc. Natl Acad. Sci. USA 108(26), 10437-10442 (2011).
81. Wang L, Xie J, Schultz PG. Expanding the genetic code. Annu. Rev. Biophys. Biomol. Struct. 35, 225-249 (2006).
82. Young TS, Schultz PG. Beyond the canonical 20 amino acids: Expanding the genetic lexicon. J. Biol. Chem. 285(15), 11039-11044 (2010).
83. Robertson SA, Ellman JA, Schultz PG. A general and efficient route for chemical aminoacylation of transfer RNAs. J. Am. Chem. Soc. 113(7), 2722-2729 (1991).
84. Robertson SA, Noren CJ, Anthony-Cahill SJ, Griffith MC, Schultz PG. The use of 5'-phospho-2 deoxyribocytidylylriboadenosine as a facile route to chemical aminoacylation of tRNA. Nucleic Acids Res. 17(23), 9649-9660 (1989).
85. Grunewald J, Hunt GS, Dong L et al. Mechanistic studies of the immunochemical termination of self-Tolerance with unnatural amino acids. Proc. Natl Acad. Sci. USA 106(11), 4337-4342 (2009).
86. Grunewald J, Tsao ML, Perera R et al. Immunochemical termination of self-Tolerance. Proc. Natl Acad. Sci. USA 105(32), 11276-11280 (2008).
87. Kessel C, Nandakumar KS, Peters FB, Gauba V, Schultz PG, Holmdahl R. A single functional group substitution in C5a breaks B and T cell tolerance and protects from experimental arthritis. Arthritis Rheumatol. 66(3), 610-621 (2013).